Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Department of Defense (DoD)-funded Phase I/II clinical study on TapImmune's HER2/neu-targeted T-cell vaccine for women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS)

Next Previous
X
Search
Trial Profile

A Department of Defense (DoD)-funded Phase I/II clinical study on TapImmune's HER2/neu-targeted T-cell vaccine for women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TPIV 110 (Primary)
  • Indications Carcinoma; Ductal carcinoma; Early breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Oct 2018 According to a Marker Therapeutics Inc, the TapImmune merged with Marker Therapeutics and changed its name to Marker Therapeutics Inc.
    • 31 Aug 2017 According to a TapImmune media release, the company plans to initiate a Phase 1b/2a clinical trial of TPIV 110 for treating women with HER2/neu+ breast cancer once an amended investigational new drug application (IND) is completed by year-end 2017 and upon FDA acceptance of the amended IND.
    • 17 Mar 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top